Capricor Therapeutics (CAPR) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $19.5 million.
- Capricor Therapeutics' Cash & Equivalents fell 7146.66% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year decrease of 7146.66%. This contributed to the annual value of $11.3 million for FY2024, which is 2319.08% down from last year.
- As of Q3 2025, Capricor Therapeutics' Cash & Equivalents stood at $19.5 million, which was down 7146.66% from $23.2 million recorded in Q2 2025.
- Over the past 5 years, Capricor Therapeutics' Cash & Equivalents peaked at $68.4 million during Q3 2024, and registered a low of $6.2 million during Q1 2024.
- In the last 5 years, Capricor Therapeutics' Cash & Equivalents had a median value of $16.4 million in 2022 and averaged $24.2 million.
- Per our database at Business Quant, Capricor Therapeutics' Cash & Equivalents crashed by 8181.93% in 2023 and then skyrocketed by 66104.55% in 2024.
- Over the past 5 years, Capricor Therapeutics' Cash & Equivalents (Quarter) stood at $34.9 million in 2021, then tumbled by 72.47% to $9.6 million in 2022, then skyrocketed by 53.02% to $14.7 million in 2023, then decreased by 23.19% to $11.3 million in 2024, then surged by 72.86% to $19.5 million in 2025.
- Its last three reported values are $19.5 million in Q3 2025, $23.2 million for Q2 2025, and $28.8 million during Q1 2025.